CANCER:

Adenoid Cystic Carcinoma

MYB underexpression MYB underexpression	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	MYB underexpression MYB underexpression	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials	tretinoin Sensitive: C3 – Early Trials
NOTCH1 mutation NOTCH1 mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	NOTCH1 mutation NOTCH1 mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials	tretinoin Sensitive: C3 – Early Trials
NOTCH mutation NOTCH mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	NOTCH mutation NOTCH mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	AL101 Sensitive: C3 – Early Trials	AL101 Sensitive: C3 – Early Trials
NOTCH1 positive + FGFR2 mutation NOTCH1 positive + FGFR2 mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	NOTCH1 positive + FGFR2 mutation NOTCH1 positive + FGFR2 mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies	lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies
MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8 MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8 MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	anlotinib + eribulin mesylate Sensitive: C4 – Case Studies	anlotinib + eribulin mesylate Sensitive: C4 – Case Studies
BCOR L1524Hfs8 BCOR L1524Hfs8	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	BCOR L1524Hfs8 BCOR L1524Hfs8	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	anlotinib Sensitive: C4 – Case Studies	anlotinib Sensitive: C4 – Case Studies
BCOR F1106Tfs5 BCOR F1106Tfs5	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	BCOR F1106Tfs5 BCOR F1106Tfs5	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	anlotinib Sensitive: C4 – Case Studies	anlotinib Sensitive: C4 – Case Studies
MYB-NFIB fusion MYB-NFIB fusion	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	MYB-NFIB fusion MYB-NFIB fusion	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	M6620 Sensitive: D – Preclinical	M6620 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	PIK3CA mutation PIK3CA mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	PI3K inhibitor Sensitive: D – Preclinical	PI3K inhibitor Sensitive: D – Preclinical
MYB fusion + PIK3CA mutation MYB fusion + PIK3CA mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	MYB fusion + PIK3CA mutation MYB fusion + PIK3CA mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	PI3K inhibitor Sensitive: D – Preclinical	PI3K inhibitor Sensitive: D – Preclinical
AXL overexpression AXL overexpression	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	AXL overexpression AXL overexpression	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	ADCT-601 Sensitive: D – Preclinical	ADCT-601 Sensitive: D – Preclinical